Manchin and Braun Call on HHS To Take Immediate Action Against Drug Manufacturers in Contract Pharmacy Battle

Sen. Joseph Manchin (D-WV) and Sen. Michael Braun (R-IN) headshots
Senators Manchin (D-WV) and Braun (R-Ind.) are urging HHS to take action against drug manufacturers who have placed restrictions in the contract pharmacy setting.

Government health officials need to take immediate action to fully enforce the law against drug makers who are denying 340B drug discounts to providers who use contract pharmacies to dispense 340B-priced drugs, U.S. Senator Joe Manchin (D-W.VA.) and U.S. Senator

Read More »

Generic/OTC Drug Maker Owes Refunds to 340B Providers, HRSA Audit Shows

screenshot of HRSA FY 2022 manufacturer audit results page
HRSA released findings from its audit of drug company VistaPharm.

The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products at the

Read More »

Breaking News

National Association of Community Health Centers Calls On Congress “To Move Urgently” To Tackle 340B Contract Pharmacy Impasse “Before It’s Too Late”

Screenshot of U.S. Dept. of Health and Human Services dispute resolutions document
After the government’s Administrative Dispute Resolution panel dismissed its complaint against drug manufacturers, NACHC is calling for Congress to take urgent action to address the contract pharmacy impasse.

Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff

Read More »

New York Times Front Page Story on 340B Program Causes Shockwaves

screenshot of New York Times article, How a Hospital Chain Used a Poor Neighborhood to Turn Huge Profits
The New York Times weekend front page story on Bon Secours Mercy Health System’s alleged misuse of the 340B program is creating a stir in the 340B community.

340B stakeholders are responding to a long investigative article in Saturday’s New York Times that accuses a Catholic health system of exploiting the 340B discount program at the expense of one of its inner-city hospitals to enrich its other hospitals

Read More »

PhRMA, BIO, and Others Unleash a Torrent of 340B Hospital Criticism

screenshot of PhRMA blog post September 15, 2022
Headline from recent blog post by PhRMA spokesperson Nicole Longo.

340B disproportionate share hospitals (DSH) in 2020 spent 2.2 times more on outpatient drugs per commercially insured patient than non-340B DSH hospitals and 2.6 times more than other types of 340B hospitals, a new drug industry-funded study shows.

The

Read More »

News Alert

Feds Tell Court They Oppose Health Center’s Effort to Sink 340B Patient Definition

Genesis Health Care, FQHC building and signage
Lawyers for HHS and HRSA told a federal district court yesterday the agencies oppose a health center’s efforts to have the longstanding 340B program definition of patient declared illegal.

Lawyers for federal healthcare officials told a federal district court yesterday that the government opposes a South Carolina health center’s efforts to have the longstanding 340B program definition of patient declared illegal.

In papers filed Sept. 22 in federal district court

Read More »

340B Report Exclusive: GAO Is Asking Hospitals if They Share 340B Savings with Low-Income Uninsured Patients at Contract Pharmacies

GAO office building
The Government Accountability Office this month recommended that HHS and Congress take long-proposed actions to better ensure 340B program compliance and Medicare’s financial stability.

A federal watchdog agency wants to know if 340B hospitals give low-income uninsured patients a break on drug prices at their contract and in-house pharmacies as part of the agency’s evaluation of a law that helps some hospitals forced out

Read More »

Merck Announces Third Round of 340B Refunds for 2019 Drug Purchases

Merck corporate campus signage
Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.

The latest round covers 15 NDCs sold during Q3 2019. The previously announced refunds were for sales during Q1

Read More »

Court Upholds $23 Million Judgement Against CVS Caremark for Unfair Pharmacy Reimbursement

Arcade claw game
CVS Caremark must pay AIDS Healthcare Foundation $23 million for Part D drug reimbursement that the PBM clawed back from AHF unfairly, a court says.

A federal district court in Arizona has upheld a $23 million arbitration award to the AIDS Healthcare Foundation (AHF) against pharmacy benefits manager (PBM) CVS Caremark for unfair drug reimbursement.

In its November 2019 lawsuit, AHF alleged that CVS Caremark

Read More »

HRSA Grants 340B Enrollment Flexibility in Puerto Rico Due to Hurricane

Puerto Rico, Hurricane Fiona, Pedro Pierluisi and other officials assess damage
Puerto Rico Gov. Pedro Pierluisi (D) (second from right), FEMA officials, and local residents assessed damage yesterday from Hurricane Fiona.

UPDATE Thursday, Sept. 22, 2022, 1:00 p.m. EDT—This story was updated to include new information from HRSA.


The U.S. Health Resources and Services Administration (HRSA) is letting eligible healthcare providers in Puerto Rico enroll in the 340B

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live